Gilead Sciences (GILD) Change in Taxes (2009 - 2026)
Gilead Sciences (GILD) reported Change in Taxes of -$29.0 million for Q1 2026, up 94.75% on a YoY basis from -$14.9 million in Q1 2025, and up 78.36% quarter-over-quarter from -$134.0 million in Q4 2025.
Gilead Sciences (GILD) Change in Taxes (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Change in Taxes for 18 years, with the latest figure at -$29.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Taxes rose 94.75% year-over-year to -$29.0 million; the trailing twelve-month figure through Mar 2026 stood at -$1.6 billion (down 47.3% YoY), and the FY2025 full-year result was -$2.1 billion, down 187.98% from the prior year.
- Change in Taxes for Q1 2026 stood at -$29.0 million, up from -$134.0 million in the prior quarter.
- The five-year high for Change in Taxes was $536.0 million in Q4 2024, with the low at -$1.3 billion in Q2 2025.
- Historically, Change in Taxes has averaged -$294.2 million across 5 years, with a median of -$134.0 million in 2025.
- The largest YoY upside for Change in Taxes was 176.79% in 2024 against a maximum downside of 4082.14% in 2024.
- Gilead Sciences' Change in Taxes stood at $119.0 million in 2022, then slumped by 686.55% to -$698.0 million in 2023, then soared by 176.79% to $536.0 million in 2024, then tumbled by 125.0% to -$134.0 million in 2025, then jumped by 78.36% to -$29.0 million in 2026.
- The last three Change in Taxes figures came in at -$29.0 million (Q1 2026), -$134.0 million (Q4 2025), and -$122.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 411.19 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -81.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 187.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | -683.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.00 Mn |
| Mar 31, 2026 | -29.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Jun 30, 2025 | -1.30 Bn |
| Jun 30, 2025 | -1.30 Bn |
| Mar 31, 2025 | -552.00 Mn |
| Mar 31, 2025 | -552.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Jun 30, 2024 | -1.17 Bn |
| Jun 30, 2024 | -1.17 Bn |
| Mar 31, 2024 | -208.00 Mn |
| Mar 31, 2024 | -208.00 Mn |
| Dec 31, 2023 | -698.00 Mn |
| Dec 31, 2023 | -698.00 Mn |